Erratum: Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: Mechanisms, impacts and therapeutic implications (Cellular and Molecular Immunology (2013) 10 (42-49) DOI: 10.1038/cmi.2012.50);Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: Mechanisms, impacts and therapeutic implications

Cellular and Molecular Immunology

Volumn 10, Issue 1, 2013, Pages 42-49

  Li, Haishan ^a   Chaudry, Suchita ^a   Poonia, Bhawna ^a   Shao, Yiming ^b   Pauza, C David ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

HIV disease; impacts; mechanisms; therapeutic implications; T cells

Indexed keywords

CELL LOSS; CELL MEDIATED CYTOTOXICITY; DISEASE ASSOCIATION; DRUG TARGETING; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOPATHOGENESIS; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; NONHUMAN; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIRUS IMMUNITY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84872175811     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.13     Document Type: Erratum

References (85)

1. Burns JM Jr, Flaherty PR, Nanavati P, Weidanz WP. Protection against plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun 2004; 72: 5605-5612. (Pubitemid 39303668)
2. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human gamma delta T cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest 1991; 87: 729-733.
3. Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune response to Mycobacterium tuberculosis antigens. Infect Immun 1991; 59: 665-670.
4. Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, Colizzi V et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol 1996; 157: 449-461. (Pubitemid 26190580)
5. de Rosa SC, Mitra DK, Watanabe N, Herzenberg LA, Roederer M. Vdelta1 and Vdelta2 γδ T cells express distinct surface markers and might be developmentally distinct lineages. J Leukoc Biol 2001; 70: 518-526. (Pubitemid 32954762)
6. Autran B, Triebel F, Katlama C, Rozenbaum W, Hercend T, Debre P. T cell receptor gamma/delta1 lymphocyte subsets during HIV infection. Clin Exp Immunol 1989; 75: 206-210. (Pubitemid 19074247)
7. Hermier F, Comby E, Delaunay A, Petitjean J, Favennec L, Bazin C et al. Decreased blood TcR gamma delta1 lymphocytes in AIDS and p24-antigenemic HIV-1-infected patients. Clin Immunol Immunopathol 1993; 69: 248-250. (Pubitemid 23319394)
8. Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, Setti M et al. Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood 2009; 113; 6611-6618.
9. Li H, Peng H, Ma P, Ruan Y, Su B, Ding X et al. Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis 2008; 46: 1466-1472. (Pubitemid 351589954)
10. Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD. Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: A mechanism for reduced tumor immunity in AIDS. J Leukoc Biol 2008; 84: 371-379.
11. Boullier S, Poquet Y, Debord T, Fournie JJ, Gougeon ML. Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons. Eur J Immunol 1999; 29: 90-99. (Pubitemid 29043526)
12. Enders PJ, Yin C, Martini F, Evans PS, Propp N, Poccia F et al. HIV-mediated γδ T cell depletion is specific for Vgamma21 cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses 2003; 19: 21-29. (Pubitemid 36398740)
13. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P et al. Selective loss of innate CD4(1) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol 2002; 76: 7528-7534. (Pubitemid 34760975)
14. Li H, Pauza CD. HIV envelope-mediated, CCR5/alpha4beta7-dependent killing of CD4-negative γδ T cells which are lost during progression to AIDS. Blood 2011; 118: 5824-5831.
15. Harris LD, Klatt NR, Vinton C, Briant JA, Tabb B, Ladell K et al. Mechanisms underlying γδ T-cell subset perturbations in SIV-infected Asian rhesus macaques. Blood 2010; 116: 4148-4157.
16. Wallace M, Scharko AM, Pauza CD, Fisch P, Imaoka K, Kawabata S et al. Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Mol Med 1997; 3: 60-71. (Pubitemid 27142525)
17. Martini F. et al. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis 2002; 186: 847-850. (Pubitemid 35013440)
18. Imlach S, Leen C, Bell JE, Simmonds P. Phenotypic analysis of peripheral blood γδ T lymphocytes and their targeting by human immunodeficiency virus type 1 in vivo. Virology 2003; 305: 415-427. (Pubitemid 36259676)
19. Medders KE, Sejbuk NE, Maung R, Desai MK, Kaul M. Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity. J Immunol 2010; 185: 4883-4895.
20. Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 2004; 4: 327-337. (Pubitemid 39552102)
21. Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 2003; 188: 1455-1460. (Pubitemid 37523930)
22. Vashistha H, Husain M, Kumar D, Singhal PC. Tubular cell HIV-1 gp120 expression induces caspase 8 activation and apoptosis. Ren Fail 2009; 31: 303-312.
23. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005; 333: 1107-1115. (Pubitemid 40910118)
24. Lin H, Chen W, Luo L,WuC, Wang Q, Liu Y. Cytotoxic effect of HIV-1 gp120 on primary cultured human retinal capillary endothelial cells. Mol Vis 2011; 17: 3450-3457.
25. Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. Patterns of chemokine receptor expression on peripheral blood gamma delta T lymphocytes: Strong expression of CCR5 is a selective feature of V delta 2/V gamma 9 gamma delta T cells. J Immunol 2002; 168: 4920-4929. (Pubitemid 34498305)
26. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384: 184-187. (Pubitemid 26386476)
27. WuL, Gerard NP, Wyatt R, Choe H, Parolin C, RuffingNet al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384: 179-183. (Pubitemid 26386475)
28. Arthos J, Cicala C, Martinelli E, Macleod K, van Ryk D, Wei D et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008; 9: 301-309. (Pubitemid 351267327)
29. Algeciras-Schimnich A, VlahakisSR, Villasis-Keever A, Gomez T, Heppelmann CJ, Bou G et al. CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS 2002; 16: 1467-1478. (Pubitemid 34804211)
30. Choi WS, Eom DS, Han BS, Kim WK, Han BH, Choi EJ et al. Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem 2004; 279: 20451-20460. (Pubitemid 38623492)
31. Schrantz N, Bourgeade MF, Mouhamad S, Leca G, Sharma S, Vazquez A. p38-mediated regulation of an Fas-associated death domain protein-independent pathway leading to caspase-8 activation during TGFbeta-induced apoptosis in human Burkitt lymphoma B cells BL41. Mol Biol Cell 2001; 12: 3139-3151. (Pubitemid 33062968)
32. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol 2011; 6: 223-248.
33. Li H, Pauza CD. The alpha4beta7 integrin binds HIV envelope but does not mediate bystander killing of γδ T cells. Blood 2012; 120: 698-699.
34. Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereyra F, Block BL et al. HLAassociated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 2009; 83: 3407-3412.
35. Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol 2012; 13: 691-700.
36. De Maria A, Ferrazin A, Ferrini S, Ciccone E, Terragna A, Moretta L. Selective increase of a subset of T cell receptor gamma delta T lymphocytes in the peripheral blood of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1992; 165: 917-919
37. Hinz T, Wesch D, Friese K, Reckziegel A, Arden B, Kabelitz D. T cell receptor gamma delta repertoire in HIV-1-infected individuals. Eur J Immunol 1994; 24: 3044-3049.
38. Wesch D, Hinz T, Kabelitz D. Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1-infected individuals. Int Immunol 1998; 10: 1067-1075. (Pubitemid 28362680)
39. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, Pauza CD. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis 2004; 189: 1482-1486. (Pubitemid 38543598)
40. Hebbeler AM, Propp N, Cairo C, Li H, Cummings JS, Jacobson LP et al. Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol 2008; 128: 349-357.
41. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR. HIV-1 natural viral suppressors: Control of viral replication in the absence of therapy. AIDS 2007; 21: 517-519.
42. Riedel DJ, Sajadi MM, Armstrong CL, Cummings JS, Cairo C, Redfield RR et al. Natural viral suppressors of HIV-1 have a unique capacity to maintain γδ T cells. AIDS 2009; 23: 1955-1964.
43. Cairo C, Armstrong CL, Cummings JS, Deetz CO, Tan M, Lu C et al. Impact of age, gender, and race on circulating γδ T cells. Hum Immunol 2010; 71: 968-975.
44. Pauza CD, Riedel DJ, Gilliam BL, Redfield RR. Targeting γδ T cells for immunotherapy of HIV disease. Future Virol 2011; 6: 73-84.
45. Boudova S, Li H, Sajadi MM, Redfield RR, Pauza CD. Impact of persistent HIV replication on CD4 negative Vgamma2Vdelta2 T cells. J Infect Dis 2012; 205: 1448-1455.
46. Cibotti R, Cabaniols JP, Pannetier C, Delarbre C, Vergnon I, Kanellopoulos JM et al. Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice. J Exp Med 1994; 180: 861-872.
47. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R et al. Positive effects of combined antiretroviral therapy on CD41 T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116. (Pubitemid 27450659)
48. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690-695. (Pubitemid 29003949)
49. Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, Katlama C et al. Perturbation of CD41 and CD81 T-cell repertoires during progression to AIDS and regulation of the CD41 repertoire during antiviral therapy. Nat Med 1998; 4: 215-221. (Pubitemid 28137377)
50. Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F et al. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated γδ T cells: Role of CD86 and inflammatory cytokines. J Immunol 2005; 174: 252-260. (Pubitemid 40007411)
51. Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E. Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol 2006; 176: 1386-1393. (Pubitemid 43134280)
52. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE et al. Human γδ T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010; 116: 1726-1733.
53. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: New insights in pathophysiology and clinical outcomes. J Leukoc Biol 2010; 88: 1119-1130.
54. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S et al. Immune modulation by zoledronic acid in human myeloma: An advantageous cross-talk between Vgamma9Vdelta2 T cells, alphabeta CD81 T cells, regulatory T cells, and dendritic cells. J Immunol 2011; 187: 1578-1590.
55. Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, Moser B. A rapid crosstalk of human γδ T cells and monocytes drives the acute inflammation in bacterial infections. PLoS Pathog 2009; 5: E1000308.
56. Li H, Luo K, Pauza CD. TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells. J Immunol 2008; 181: 7131-7137.
57. Poccia F, Cipriani B, Vendetti S, Colizzi V, Poquet Y, Battistini L et al. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes. J Immunol 1997; 159: 6009-6017. (Pubitemid 127471537)
58. Tikhonov I, Deetz CO, Paca R, Berg S, Lukyanenko V, Lim JK et al. Human Vgamma2Vdelta2 T cells contain cytoplasmic RANTES. Int Immunol 2006; 18: 1243-1251. (Pubitemid 44349299)
59. Lehner T, Wang Y, Whittall T, Seidl T. Innate immunity and HIV-1 infection. Adv Dent Res 2011; 23: 19-22.
60. Cipriani B, Borsellino G, Poccia F, Placido R, Tramonti D, Bach S et al. Activation of CC beta-chemokines in human peripheral blood γδ T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 2000; 95: 39-47. (Pubitemid 30017222)
61. Poccia F, Battistini L, Cipriani B, Mancino G, Martini F, Gougeon ML et al. Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis 1999; 180: 858-861. (Pubitemid 29411378)
62. Caccamo N, la Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G et al. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells. Blood 2011; 118: 129-138.
63. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of human γδ T cells to provide B-cell help. Eur J Immunol 2012; 42: 110-119.
64. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, van Rysselberge M et al. Human cytomegalovirus elicits fetal γδ T cell responses in utero. J Exp Med 2010; 207: 807-821.
65. Dechanet J, Merville P, Lim A, Retie' re C, Pitard V, Lafarge X et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103: 1437-1449. (Pubitemid 29535500)
66. Dechanet J, Merville P, Bergé F, Bone-Mane G, Taupin JL, Michel P et al. Major expansion of γδ T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis 1999; 179: 1-8. (Pubitemid 29028331)
67. Tu W, Zheng J, Liu Y, Sia SF, Liu M, Qin G et al. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized mice. J Exp Med 2011; 208: 1511-1522.
68. Qin G, Mao H, Zheng J, Sia SF, Liu Y, Chan PL et al. Phosphoantigen- expanded human γδ T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis 2009; 200: 858-865.
69. Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA. A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human γδ T lymphocytes. Cell Immunol 2010; 264: 71-77.
70. Fausther-Bovendo H, Wauquier N, Cherfils-Vicini J, Cremer I, Debré P, Vieillard V. NKG2C is a major triggering receptor involved in the V[delta]1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. AIDS 2008; 22: 217-226.
71. Hudspeth K, Fogli M, Correia DV, Mikulak J, Roberto A, Della Bella S et al. Engagement of NKp30 on Vdelta1 T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication. Blood 2012; 119: 4013-4016.
72. Wallace M, Bartz SR, Chang WL, Mackenzie DA, Pauza CD, Malkovsky M. Gamma delta T lymphocyte responses to HIV. Clin Exp Immunol 1996; 103: 177-184.
73. Poccia F, Gougeon ML, Agrati C, Montesano C, Martini F, Pauza CD et al. Innate T-cell immunity in HIV infection: The role of Vgamma9Vdelta2 T lymphocytes. Curr Mol Med 2002; 2: 769-781. (Pubitemid 35390312)
74. Capietto AH, Martinet L, Fournie JJ. Stimulated γδ T cells increase the in vivo efficacy of trastuzumab inHER-21 breast cancer. J Immunol 2011; 187: 1031-1038.
75. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P et al. Antibodydependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcgammaRIIIa). Blood 2012; 119: 1418-1427.
76. Qin G, Liu Y, Zheng J, Xiang Z, Ng IH, Malik Peiris JS et al. Phenotypic and functional characterization of human γδ T-cell subsets in response to influenza A viruses. J Infect Dis 2012; 205: 1646-1653.
77. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR et al. Isopentenyl pyrophosphate-activated CD561 {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 2008; 14: 4232-4240.
78. Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A et al. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med 1990; 171: 1567-1579. (Pubitemid 20167551)
79. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-194. (Pubitemid 351705208)
80. Shiels MS, Engels EA. Increased risk of histologically defined cancer subtypes in human immunodeficiency virus-infected individuals: Clues for possible immunosuppression-related or infectious etiology. Cancer 2012; 118: 4869-4876.
81. Biggar RJ, Engels EA, Frisch M, Goedert JJ. Risk of T-cell lymphomas in persons with AIDS. J Acquir Immune Defic Syndr 2001; 26: 371-376. (Pubitemid 32436004)
82. Lamb LS Jr, Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ et al. Human γδ(1) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 2001; 27: 601-606. (Pubitemid 32401457)
83. Meeh PF, King M, O'Brien RL, Muga S, Buckhalts P, Neuberg R et al. Characterization of the γδ T cell response to acute leukemia. Cancer Immunol Immunother 2006; 55: 1072-1080. (Pubitemid 43800722)
84. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS 2009; 23: 555-565.
85. Poonia B, Pauza CD. Gamma delta T cells from HIV1 donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy 2012; 14: 173-181.